avasopasem
Phase 2- Indications
- Hormone receptor-positive breast cancer
Company intelligence / Profile preview
Galera Therapeutics, Inc.
Malvern, Pennsylvania, USAgaleratx.com ↗
- Ownership
- Public · GRTX
- Employees
- ~3
- Development stage
- Phase 2
01
Overview
Galera’s lead candidate avasopasem manganese completed a Phase III trial for severe oral mucositis in head and neck cancer but did not meet its primary endpoint for statistical significance despite showing some reduction trends. Rucosopasem manganese showed safety and early efficacy signals in NSCLC with ongoing Phase II work at the time of company wind-down. The company also had early-stage programs targeting breast cancers using NOS inhibitors.
- Therapeutic areas
- OncologyNephrology
- Modalities
- Small molecules (specifically superoxide dismutase mimetics)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Galera Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galera Therapeutics, Inc..